Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Genitourinary Cancer

    EU Genitourinary Cancer Partner

    World Genitourinary Cancer Partner

    An Introduction to Genitourinary Cancer

    Genitourinary cancers incorporate the sub-specialities of prostate, kidney, bladder and testicular cancer. Advances in immunotherapies, targeted therapies and combination therapies have improved patient outcomes over recent years.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Genitourinary Cancer Content

    Bladder Cancer, Genitourinary Cancer
    Developed by Touch
    Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer
    Thomas Powles Watch Time: 6 minutes

    The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + RC followed by adjuvant durvalumab or NAC + RC alone. The study […]

    Genitourinary Cancer, Prostate Cancer
    Is prostate cancer overdiagnosis a risk in Europe’s screening efforts?

    A recent study examining prostate cancer trends across 26 European countries has provided vital data for the ongoing discussions around implementing EU-wide screening programs.

    Breast Cancer, Dermatological Cancers, Lung Cancer, Renal Cancer
    ESMO Congress 2024 – 13 – 17 September, Barcelona Spain

    We’re looking forward to the ESMO Congress 2024 which is taking place in Madrid between 13- 17  September, 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of oncology, we are excited to provide independent, expert video coverage of key data. You can sign up here to receive […]

    Breast Cancer, Dermatological Cancers, Gastrointestinal Cancers, Genitourinary Cancer, Gynaecological Cancers, Haematological Malignancies, Haematology, Head and Neck Cancer, Immunotherapy, Lung Cancer, Endocrine Cancers, Paediatric Oncology
    Space medicine: Can microgravity transform pharmaceutical manufacturing?

    In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

    Renal Cancer, Genitourinary Cancer, Immunotherapy
    Watch Time: 18 mins
    touchFOCUS
    Personalizing care within the MDT for patients with early through to advanced RCC
    CE/CME ACCREDITED Prof. Hans Hammers

    Watch an expert in RCC discuss multidisciplinary team care for patients with early through advanced disease.

    Learning objectives
    Learning Objectives
    • Apply diagnostic and prognostic markers and clinical data within the MDT to personalize care for patients with early stage through advanced and metastatic renal cell carcinoma
    • Use effective communication strategies and encourage shared decision-making when managing diverse and/or underserved patients with renal cell carcinoma
    Genitourinary Cancer, Prostate Cancer, Radiology
    New study shows combined power of deep learning and radiologists in prostate cancer detection

    A new study published in the Journal of Radiology reveals promising advancements in the use of artificial intelligence (AI) to improve radiology reporting, particularly in the context of prostate cancer detection. The research demonstrates that AI can significantly enhance the accuracy and efficiency of radiological assessments, especially in complex cases involving large sets of imaging data.

    Bladder Cancer, Genitourinary Cancer
    Developed by Touch
    Insights in bladder cancer: EV-302, EV-101, CheckMate 901
    Petros Grivas Watch Time: 9 mins

    Significant advancements in bladder cancer research emerged from ASCO 2024. To understand these, as well as the other key trials and highlights from the meeting, we spoke with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas. In this interview, Prof. Grivas delves into the findings from the EV-302 (NCT04223856), EV-101 (NCT02091999), EV-201 (NCT03219333), EV-301 (NCT03474107), CheckMate 901 (NCT03036098) and other trials, offering his valuable insights into the impact the results could have on clinical practice, and particularly in the treatment of bladder

    Bladder Cancer, Genitourinary Cancer, Immunotherapy
    Watch Time: 32 mins
    touchEXPERT OPINIONS
    Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape
    CE/CME ACCREDITED Prof. Thomas Powles Translations available:

    Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.

    Learning objectives
    Learning Objectives
    • Choose appropriate treatments for patients with advanced urothelial carcinoma who are ineligible for or whose disease does not respond to first-line platinum-based chemotherapy
    • Outline how new and emerging therapies can be integrated in the treatment algorithm for advanced urothelial carcinoma
    • Manage adverse events of newly approved agents and combination therapies
    Genitourinary Cancer, Bladder Cancer
    Watch Time: 16 mins
    touchFOCUS
    Is HER2 targeting on the horizon in urothelial carcinoma?
    CE/CME ACCREDITED Dr Vadim Koshkin

    A GU oncologist shares insights into HER2 overexpression, testing and targeting in urothelial carcinoma.

    Learning objectives
    Learning Objectives
    • Discuss the clinical significance of HER2 expression in patients with urothelial carcinoma and considerations for molecular testing
    • Evaluate emerging HER2-targeting treatment strategies for patients with urothelial carcinoma and the latest clinical evidence
    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup